Published on : Dec 01, 2016
ALBANY, NY, Dec 01, 2016: The report presents a detailed overview of the state of innovation in the cardiovascular disease (CVD) market in the context of the current state of competitive landscape and pipeline drugs. The report also includes a thorough analysis of the key co-development and licensing deals taking place in the market. Key cardiovascular indications examined in detail in the report include dyslipidemia, thrombotic events, and hypertension. Of the key treatment methods for the treatment of cardiovascular disease, the report examines the segments of anti-hypertensive drugs, anti-dyslipidemia drugs, and anti-thrombotic drugs. Anti-hypertensive drugs help lower blood pressure, anti-dyslipidemia drugs help alter lipid levels to a healthy level in the body, and anti-thrombotic drugs help prevent the formation of thrombus and mitigate the damage of a current aim to either prevent thrombus forming or work to alleviate the damage of a current thrombi.
The global CVD therapeutic market has witnessed vast scientific innovations in the past few decades, particularly in the field of anti-dyslipidemia. The introduction of statins such as Lipitor, the atorvastatin calcium tablets manufactured by Pfizer, which has shown excellent results in the reduction of cholesterol levels, is expected to significantly drive the global CVD market in the next few years.
Recently, Xa inhibitors, which are known to have anti-coagulant properties, have also been made publicly available in the form of oral administration. The easy availability of PCSK9 inhibitors, which are an efficient alternative to the treatment of dyslipidemia when statins are inefficient or are unsuitable, is also expected to drive the market.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=869174
The global CVD market presently has over 1368 pipeline drugs. Of these, the largest number of pipeline drugs are in the thrombosis therapeutic area. The report states that over 400 drugs are in pipeline that are indicated to be useful for the prevention and/or treatment of thrombotic events. Drugs expected to be imminently released in the global CVD market include a mix of several first-in-class products, especially anti-dyslipidemia medicines expected to provide alternative to statin, and medicines for highly popular drug classes such as the Xa inhibitors and PCSK9 inhibitors.
The report presents a brief introduction to the various cardiovascular conditions rampant across the world, including common symptoms, pathophysiology, and a thorough account of the pharmacotherapy for these conditions. The report identifies some of the most popular marketed products in the global CVD market, with a focus on historical and future sales patterns and the mechanisms of action of each of these diseases.
Data such as the stage of development, molecule target, and molecule type of the key pipeline drugs in the market are furnished. A detailed overview of the competitive landscape of the global CVD market, by providing detailed identification and assessment of key companies in the market in terms of growth prospects and share in the global market, is also included in the report.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org